Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Related topics
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer
Nov 29, 2021
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
How to Improve Your Viral Nucleic Acid Extraction Processes
Sep 6, 2021
High-Throughput Extraction with CyBio FeliX
Comparison of gamma and x-ray irradiation results
Aug 12, 2021
Biological effects of Cs-137 and X-ray irradiators are comparable with regards to...
Hypoxia further exacerbates myopathy in broilers via alteration of satellite cell fate
Aug 2, 2021
Woody breast (WB) condition has created a variety of challenges for the global poultry...
High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma
Jul 21, 2021
Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence,...
Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles
Jul 3, 2021
Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma....
Quantitative two-photon microscopy imaging analysis of human skin
Jul 1, 2021
Transdermal skin delivery is a method to transport various topical formulations to a deeper skin layer non-invasively....
Elevated NSD3 histone methylation activity drives squamous cell lung cancer
Jun 8, 2021
This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in...
Single-cell DNA Analysis of a Novel Acute Erythroid Leukemia CRISPR Induced Mouse Model
May 9, 2021
Assessment of precise genetic edits. Analysis of the clonal structure & co-mutations of AEL. Use of CRISPR and...
Aug 9, 2016
At the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Anna Wu, Ph.D., professor and chair of the department of molecular and medical pharmacology, has been engineering antibodies for both therapeutic and imaging purposes. Antibodies meant for imaging, she points out, reflect a slightly different set of engineering characteristics.
Dr. Wu works with colleagues at UCLA and ImaginAb (a company she co-founded in 2007 and now serves as chief scientist) to engineer labeled antibodies. Because Dr. Wu in interested in advancing positron emission tomography (PET) imaging, she is engineering antibodies that incorporate positron-emitting radionucleotides.
“Each imaging modality has its strengths and weaknesses,” notes Dr. Wu. “Magnetic resonance imaging (MRI) gives you anatomical and physiological imaging, but it doesn’t have the sensitivity of PET. PET has a higher resolution and sensitivity compared to single-photon emission computed tomography (SPECT), but it has lower resolution than MRI or CT.”
Dr. Wu has chosen PET because it fits well with her antibody fragments (called minibodies and diabodies) in a process coined immunoPET. She favors PET because it can, she says, be combined with the specificity of antibodies.
“One of the key features of antibodies is they have very long circulating half-lives,” she points out. “Antibodies stay in the blood for days to weeks.” To match the half-lives of antibodies, she and others have been testing longer-lived positron emitters, such as zirconium-89. “The fluorine-18 everyone uses has a two-hour half-life, so it’s a challenge to make a fragment that targets and clears quickly enough to image.” Zirconium-89, in contrast, has a half-life that is a little over three days.
Related technologies: PET, SPECT, CT
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com/